November 29, 2016 - By Adrian Mccoy
Stock research analysts at finnCap have GBX 200.00 PT on Avacta Group PLC (LON:AVCT). finnCap’s PT indicates a potential upside of 125.99% from the company’s close price. The rating was disclosed to clients in a research note on Tuesday, 29 November.
Out of 2 analysts covering Avacta Group PLC (LON:AVCT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 200 is the highest target while GBX 1.60 is the lowest. The GBX 180 average target is 106.78% above today’s (GBX 87.05) stock price. Avacta Group PLC has been the topic of 9 analyst reports since October 26, 2015 according to StockzIntelligence Inc. FinnCap maintained Avacta Group Plc (LON:AVCT) on Wednesday, November 23 with “Corporate” rating. FinnCap maintained the shares of AVCT in a report on Tuesday, November 1 with “Corporate” rating. The stock of Avacta Group Plc (LON:AVCT) has “Buy” rating given on Monday, August 1 by Numis Securities. The rating was maintained by Numis Securities with “Buy” on Wednesday, August 3. The stock of Avacta Group Plc (LON:AVCT) has “Corporate” rating given on Monday, October 17 by FinnCap. Numis Securities reinitiated Avacta Group Plc (LON:AVCT) rating on Monday, April 25. Numis Securities has “Buy” rating and GBX 160 price target. The stock of Avacta Group Plc (LON:AVCT) has “Corporate” rating given on Thursday, September 22 by FinnCap.
About 5,089 shares traded hands. Avacta Group Plc (LON:AVCT) has declined 21.33% since April 29, 2016 and is downtrending. It has underperformed by 26.59% the S&P500.
Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The company has a market cap of 60.52 million GBP. The Company’s divisions include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. It currently has negative earnings. The Company’s in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies.
More news for Avacta Group Plc (LON:AVCT) were recently published by: Uk.Finance.Yahoo.com, which released: “Avacta Group Plc (AVCT.L)” on January 07, 2014. Fool.Co.Uk‘s article titled: “Avacta Group Plc Jumps After Transformational Moderna Therapeutics Deal” and published on May 18, 2015 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy